The group set up to battle AIDS, tuberculosis and malaria, described the deal to procure lenacapavir for low- and middle-income countries (LMICs) as “a significant milestone for global health equity”.
The group said it hoped the agreement with Gilead would make it possible to reach two million people with the revolutionary drug, which was approved by the US Food and Drug Administration last month.
By contrast, lenacapavir, marketed under the brand name Yeztugo, requires only two injections per year and has been shown to reduce the risk of HIV transmission by more than 99.9 percent in adults and adolescents -- making it functionally akin to a powerful vaccine.
“For the first time, we have a tool that can fundamentally change the trajectory of the HIV epidemic -- but only if we get it to the people who need it most.”
This, it said, would mark the start of “a transformational shift in how HIV prevention is delivered to communities with the highest burden of new infections”.
“This is a game changer for South Africa,“ South African Health Minister Aaron Motsoaledi said in the statement.
“Lenacapavir offers young women, and everyone at risk, a discreet, long-acting option to stay HIV-free.” – AFP
Read More Details
Finally We wish PressBee provided you with enough information of ( Poorer countries granted access to HIV prevention drug )
Also on site :